



Supporting Information

for

Synthesis and physical properties of tunable aryl alkyl ionic liquids based on 1-aryl-4,5-dimethylimidazolium cations

Stefan Fritsch and Thomas Strassner

Beilstein J. Org. Chem. **2024**, *20*, 1278–1285. doi:10.3762/bjoc.20.110

Experimental procedures and characterization data

Contents

Section S1 Synthesis of imidazole derivatives	S2–S7
Section S2 Synthesis of imidazolium bromides	S8–S21
Section S3 Synthesis of NTf ₂ -ionic liquids	S22–S35
Section S4 Electrochemical measurements	S36–S40
Section S5 Viscosity measurements	S40–S44
Section S6 Thermogravimetric analysis	S45–S58
Section S7 NMR-Spectra	S59–S104
Section S8 Cartesian coordinates of optimized structures	S105–S109
Section S9 References	S110

S1 Synthesis of imidazole derivatives


General informations

NMR spectroscopic data were recorded at room temperature with a Bruker AV II 300 spectrometer and a Bruker AV III 600 spectrometer. Chemical shifts δ are referenced to solvent signals [^1H NMR: CDCl_3 (7.26 ppm); ^{13}C NMR: CDCl_3 (77.16 ppm)]. ^{19}F spectra were referenced externally to trifluoromethylbenzene in CDCl_3 . Chemical shifts are given in ppm, coupling constants J are given in Hertz (Hz). Signal patterns are indicated as s, singlet; d, doublet; dd, double doublet; t, triplet; q, quartet; quin, quintet; sxt, sextet; m, multiplet. Before any physicochemical measurements were conducted, all NTf_2 ionic liquids were heated to 120 °C under vigorous stirring and a vacuum of 0.001 mbar was applied. The ionic liquid was stirred at this temperature for 15 minutes and was allowed to cool to room temperature under vacuum with continued stirring. The ionic liquids were flushed with and stored under argon. Elemental analyses were performed with a Thermo Fisher Scientific FlashSmart elemental analyzer. Viscosities were determined using a Brookfield DV2T viscosimeter with a CPA-52 rotating disc. The viscosimeter was calibrated using Brookfield "CAP2L" viscosity standard with 177 cp at 25 °C. The viscosity accuracy is $\pm 1\%$. The measurements were carried out from 25 °C to 65 °C in 5 °C steps. Conductivities were measured at 25 °C with a Mettler Toledo cond probe InLab 752–6 mm connected to a Mettler Toledo Seven Easy conductivity meter with an uncertainty of $\pm 4 \mu\text{S}/\text{cm}$. The conductivity meter was calibrated using conductivity standard 1413 $\mu\text{S}/\text{cm}$ from Hanna Instruments. Melting points were determined by using a Wagner and Munz PolyTherm A system and are given uncorrected. Linear sweep voltammetry (LSV) was performed in pure ionic liquid using a BioLogic SP-150 potentiostat with a glassy carbon working electrode (diameter 3 mm), a Pt-wire counter electrode and an Ag-wire as a pseudo reference electrode. The measurements were conducted with a sweep rate of 50 mV/s. The electrochemical window was determined with a cut-off current density of 0.1 mA/cm^2 . Thermogravimetric analyses were performed using a Netzsch TG209 F1 Libra with Al_2O_3 crucibles. The measurements were conducted under an argon atmosphere with a heating rate of 10 °C/min (25–500 °C). The decomposition temperature was set at 5% mass loss. The TGA sample chamber containing the sample was purged and flushed with argon three times before starting the measurement.

General procedure for the synthesis of 4,5-dimethyl-1-phenylimidazoles

To a solution of butane-2,3-dione monoxime (400 mmol, 1.0 equiv) in 400 ml acetic acid, $\text{BF}_3 \cdot \text{OEt}_2$ (440 mmol, 1.1 equiv), formaldehyde (400 mmol, 1.0 equiv) and the corresponding aniline (400 mmol, 1.0 equiv) were added, and the solution was stirred at 50 °C for 4 hours. After 4 hours, iron powder (1.80 mol, 4.5 equiv) was added and the solution was refluxed for 2 hours. Afterwards, the reaction mixture was poured into water and the iron residue was removed via filtration. The filtrate was extracted with chloroform and the organic phase was washed with 10% aqueous potassium carbonate solution until no further gas evolution was observed. The organic layer was washed with distilled water, dried over sodium sulfate and filtered. The chloroform was removed under reduced pressure. The crude product was purified via vacuum distillation.

4,5-Dimethyl-1-phenyl-1*H*-imidazole (1)¹




Following the general procedure using 200 mmol of aniline, the product was obtained with a yield of 50% (17.2 g, 100 mmol) as a yellow oil.

¹H NMR: (300MHz, CDCl_3) δ 7.39 - 7.56 (m, 4 H), 7.22 - 7.29 (m, 2 H), 2.24 (s, 3 H), 2.09 (s, 3 H).

¹³C NMR: (75 MHz, CDCl_3) δ 136.8, 134.9, 134.0, 129.5, 128.2, 125.5, 123.1, 12.6, 9.1.

Melting point: liquid at room temperature.

4,5-Dimethyl-1-(*p*-tolyl)-1*H*-imidazole (2)²




Following the general procedure using 200 mmol of aniline, the product was obtained with a yield of 43% (15.9 g, 85 mmol) as a light yellow oil.

¹H NMR: (300MHz, CDCl_3) δ 7.47 (s, 1 H), 7.22 - 7.30 (m, 2 H), 7.10 - 7.16 (m, 2 H), 2.40 (s, 3 H), 2.22 (s, 3 H), 2.07 (s, 3 H).

¹³C NMR: (75 MHz, CDCl_3) δ 138.2, 134.9, 134.2, 133.8, 130.0, 125.3, 123.1, 21.0, 12.6, 9.0.

Melting point: liquid at room temperature.

1-(4-Methoxyphenyl)-4,5-dimethyl-1*H*-imidazole (3)³




Following the general procedure using 400 mmol of aniline, the product was obtained with a yield of 40% (32 g, 158 mmol) as a light yellow oil that solidified upon standing.

¹H NMR: (300MHz, CDCl₃) δ 7.47 (s, 1 H), 7.13 - 7.21 (m, 2 H), 6.92 - 7.01 (m, 2 H), 3.85 (s, 3 H), 2.22 (s, 3 H), 2.05 (s, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 159.3, 135.0, 133.5, 129.6, 126.9, 123.4, 114.5, 55.5, 12.6, 8.9.

Melting point: 51°C.

1-(4-Bromophenyl)-4,5-dimethyl-1*H*-imidazole (4)




Following the general procedure using 400 mmol of aniline, the product was obtained with a yield of 53% (53.5 g, 213 mmol) as a light yellow oil that solidified upon standing.

¹H NMR: (300MHz, CDCl₃) δ 7.62 (m, 2 H), 7.56 (s, 1 H), 7.15 (m, 2 H), 2.24 (s, 3 H), 2.09 (s, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 135.6, 134.6, 134.1, 132.8, 127.0, 123.0, 122.2, 12.5, 9.0.

Melting point: 64°C.

4,5-Dimethyl-1-(4-(trifluoromethyl)phenyl)-1*H*-imidazole (5)



Following the general procedure using 400 mmol of aniline, the product was obtained with a yield of 44% (42.2 g, 176 mmol) as a clear oil that solidified upon standing.


¹H NMR: (300MHz, CDCl₃) δ 7.77 (m, 2 H), 7.66 (d, *J* = 8.80 Hz, 1 H), 7.42 (m, 2 H), 2.26 (s, 3 H), 2.14 (s, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 139.5, 134.6, 130.7, 126.9 (q, *J* = 3.6 Hz), 125.6, 123.0, 121.8, 12.4, 9.2.

¹⁹F NMR: (282 MHz, CDCl₃) δ -63.2.

Melting point: 74°C.

4,5-Dimethyl-1-(4-(trifluoromethoxy)phenyl)-1*H*-imidazole (6)



Following the general procedure using 400 mmol of aniline, the product was obtained with a yield of 56% (57.8 g, 225 mmol) as a light yellow oil.


¹H NMR: (300MHz, CDCl₃) δ 7.56 (s, 1 H), 7.24 - 7.38 (m, 4 H), 2.24 (s, 3 H), 2.10 (s, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 148.7, 134.8, 127.0, 125.5, 123.1, 122.0, 118.6, 12.5, 9.0.

¹⁹F NMR: (282 MHz, CDCl₃) δ -58.6.

Melting point: liquid at room temperature.

4,5-Dimethyl-1-(*o*-tolyl)-1*H*-imidazole (7)⁴




Following the general procedure using 400 mmol of aniline, the product was obtained with a yield of 41% (30.3 g, 163 mmol) as a light yellow oil.

¹H NMR: (300MHz, CDCl₃) δ 7.23 - 7.38 (m, 4 H), 7.12 (d, *J* = 7.7 Hz, 1 H), 2.22 (s, 3 H), 2.02 (s, 3 H), 1.89 (s, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 135.6, 134.8, 133.3, 130.9, 129.1, 127.8, 126.7, 123.4, 17.2, 12.6, 8.4.

Melting point: liquid at room temperature.

1-(2-Methoxyphenyl)-4,5-dimethyl-1*H*-imidazole (8)¹




Following the general procedure using 400 mmol of aniline, the product was obtained with a yield of 28% (22.9 g, 113 mmol) as a light yellow oil that solidified upon standing.

¹H NMR: (300MHz, CDCl₃) δ 7.43 (s, 1 H), 7.37 - 7.42 (m, 1 H), 7.12 - 7.19 (m, 1 H), 7.00 - 7.06 (m, 2 H), 3.78 (s, 3 H), 2.23 (s, 3 H), 1.96 (s, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 154.6, 135.4, 132.6, 130.0, 128.4, 125.4, 124.2, 120.7, 112.0, 55.6, 12.6, 8.5.

Melting point: 75°C.

1-(2,4-Difluorophenyl)-4,5-dimethyl-1*H*-imidazole (9)



Following the general procedure using 400 mmol of aniline, the product was obtained with a yield of 52% (43.0 g, 207 mmol) as a light yellow oil that solidified upon standing.

^1H NMR: (300MHz, CDCl_3) δ 7.56 (m, 1 H), 7.21 - 7.30 (m, 1 H), 6.94 - 7.04 (m, 2 H), 2.25 (s, 3 H), 2.01 (s, 3 H).

^{13}C NMR: (75 MHz, CDCl_3) δ 164.2 (dd, $J = 262.9, 10.7$ Hz), 159.1 (dd, $J = 267.0, 12.5$ Hz), 135.3, 133.8, 129.6 (dd, $J = 11.3, 1.2$ Hz), 123.9, 112.2 (dd, $J = 26.2, 4.2$ Hz), 105.6 (dd, $J = 50.1, 23.8$ Hz), 12.5, 8.3.

^{19}F NMR: (282 MHz, CDCl_3) δ -106.9, -116.6.


Melting point: 45 °C.

S2 Synthesis of imidazolium bromides

General procedure for the synthesis of the imidazolium bromides

In an ACE pressure tube the corresponding aryl-imidazole (34 mmol) is dissolved in 17 mL of THF and 1.1 equiv of the corresponding alkyl bromide is added. The solution is stirred at 75 °C for 72 h. Afterwards the reaction mixture is allowed to cool to room temperature and the solvent was removed in vacuo. The crude product is then washed with diethyl ether and isohexane.

3-Butyl-4,5-dimethyl-1-phenyl-1*H*-imidazol-3-ium bromide (10)




Following the general procedure, 34 mmol of imidazole **1** were alkylated using 1-bromobutane. The product was obtained as a brown solid (9.6 g, 31 mmol, 92%).

¹H NMR: (300MHz, CDCl₃) δ 10.09 (s, 1 H), 7.37 - 7.56 (m, 5 H), 4.43 (t, *J* = 7.6 Hz, 2 H), 2.30 (s, 3 H), 2.13 (s, 3 H), 1.83 (quin, *J* = 7.6 Hz, 2 H), 1.40 (sxt, *J* = 7.5 Hz, 2 H), 0.92 (t, *J* = 7.3 Hz, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 135.6, 133.0, 130.5, 130.1, 126.8, 126.7, 125.7, 47.3, 31.9, 19.4, 13.4, 9.2, 8.6.

Melting point: 55 °C.

4,5-Dimethyl-3-octyl-1-phenyl-1*H*-imidazol-3-ium bromide (11)




Following the general procedure, 32 mmol of imidazole **1** were alkylated using 1-bromooctane. The product was obtained as a brown solidified melt (11.1 g, 30 mmol, 96%).

¹H NMR: (300MHz, CDCl₃) δ 10.09 (s, 1 H), 7.43 - 7.58 (m, 5 H), 4.35 - 4.49 (m, 2 H), 2.30 (s, 3 H), 2.14 (s, 3 H), 1.79 - 1.92 (m, 2 H), 1.14 - 1.36 (m, 10 H), 0.75 - 0.86 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 135.6, 133.1, 130.5, 130.2, 126.8, 126.7, 125.7, 47.5, 31.6, 30.1, 28.9, 26.2, 22.4, 13.9, 9.2, 8.7.

Melting point: solidified melt.

3-Dodecyl-4,5-dimethyl-1-phenyl-1*H*-imidazol-3-ium bromide (12)




Following the general procedure, 30 mmol of imidazole **1** were alkylated using 1-bromododecane. The product was obtained as a brown solidified melt (11.7 g, 28 mmol, 93%).

¹H NMR: (300MHz, CDCl₃) δ 10.13 (s, 1 H), 7.45 - 7.60 (m, 5 H), 4.44 (t, *J* = 7.6 Hz, 2 H), 2.31 (s, 3 H), 2.15 (s, 3 H), 1.80 - 1.94 (m, 2 H), 1.13 - 1.31 (m, 18 H), 0.79 - 0.88 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 135.8, 133.1, 130.6, 130.2, 126.7, 126.6, 125.7, 47.6, 31.7, 30.2, 29.5, 29.4, 29.4, 29.3, 29.2, 29.0, 26.3, 22.5, 14.0, 9.2, 8.7.

Melting point: solidified melt.

3-Butyl-4,5-dimethyl-1-(*p*-tolyl)-1*H*-imidazol-3-ium bromide (13)




Following the general procedure, 31 mmol of imidazole **2** were alkylated using 1-bromobutane. The product was obtained as a brown oil (9.6 g, 30 mmol, 96%).

¹H NMR: (300MHz, CDCl₃) δ 10.06 (s, 1 H), 7.21 - 7.38 (m, 4 H), 4.32 - 4.48 (m, 2 H), 2.36 (s, 3 H), 2.29 (s, 3 H), 2.11 (s, 3 H), 1.73 - 1.90 (m, 2 H), 1.39 (m, 2 H), 0.84 - 0.96 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 141.2, 135.8, 130.9, 130.8, 121.8, 126.8, 125.7, 47.5, 32.3, 21.3, 19.7, 13.7, 9.4, 8.9.

Melting point: liquid at room temperature.

4,5-Dimethyl-3-octyl-1-(*p*-tolyl)-1*H*-imidazol-3-ium bromide (14)




Following the general procedure, 26 mmol of imidazole **2** were alkylated using 1-bromooctane. The product was obtained as a brown solidified melt (9.5 g, 25 mmol, 95%).

¹H NMR: (300MHz, CDCl₃) δ 10.06 (s, 1 H), 7.31 (m, 4 H), 4.40 - 4.47 (m, 2 H), 2.38 (s, 3 H), 2.30 (s, 3 H), 2.13 (s, 3 H), 1.84 - 1.92 (m, 2 H), 1.22 - 1.40 (m, 10 H), 0.78 - 0.88 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 141.0, 135.7, 130.7, 130.5, 126.9, 126.5, 125.5, 47.5, 31.6, 30.2, 29.0, 28.9, 26.2, 22.5, 21.1, 13.9, 9.2, 8.7.

Melting point: solidified melt.

3-Dodecyl-4,5-dimethyl-1-(*p*-tolyl)-1*H*-imidazol-3-ium bromide (15)




Following the general procedure, 23 mmol of imidazole **2** were alkylated using 1-bromo-dodecane. The product was obtained as a brown solidified melt (9.4 g, 22 mmol, 94%).

¹H NMR: (300MHz, CDCl₃) δ 10.06 (s, 1 H), 7.27 - 7.36 (m, 4 H), 4.36 - 4.47 (m, 2 H), 2.38 (s, 3 H), 2.30 (s, 3 H), 2.13 (s, 3 H), 1.77 - 1.93 (m, 2 H), 1.21 - 1.38 (m, 18 H), 0.78 - 0.88 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 140.9, 135.7, 130.7, 130.5, 126.8, 126.5, 125.5, 47.5, 31.7, 30.2, 29.5, 29.5, 29.4, 29.3, 29.2, 29.0, 26.2, 22.5, 21.1, 14.0, 9.2, 8.7.

Melting point: solidified melt.

3-Butyl-1-(4-methoxyphenyl)-4,5-dimethyl-1*H*-imidazol-3-ium bromide (16)




Following the general procedure, 55 mmol of imidazole **3** were alkylated using 1-bromobutane. The product was obtained as a brown solid (17.8 g, 53 mmol, 95%).

¹H NMR: (300MHz, CDCl₃) δ 10.01 (s, 1 H), 7.38 (m, 2 H), 6.97 (m, 2 H), 4.40 (t, *J* = 7.6 Hz, 2 H), 3.80 (s, 3 H), 2.28 (s, 3 H), 2.10 (s, 3 H), 1.83 (quin, *J* = 7.6 Hz, 2 H), 1.40 (sxt, *J* = 7.5 Hz, 2 H), 0.92 (t, *J* = 7.4 Hz, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 160.8, 135.7, 127.1, 127.1, 126.4, 125.6, 115.3, 115.2, 55.6, 47.2, 31.9, 19.5, 13.4, 9.1, 8.6.

Melting point: 58 °C.

1-(4-Methoxyphenyl)-4,5-dimethyl-3-octyl-1*H*-imidazol-3-ium bromide (17)




Following the general procedure, 50 mmol of imidazole **3** were alkylated using 1-bromooctane. The product was obtained as a brown solid (19.3 g, 49 mmol, 98%).

¹H NMR: (300MHz, CDCl₃) δ 10.01 (s, 1 H), 7.36 - 7.44 (m, 2 H), 6.94 - 7.03 (m, 2 H), 4.36 - 4.46 (m, 2 H), 3.81 (s, 3 H), 2.29 (s, 3 H), 2.11 (s, 3 H), 1.78 - 1.92 (m, 2 H), 1.15 - 1.34 (m, 10 H), 0.79 - 0.84 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 160.9, 135.8, 127.1, 127.1, 126.4, 125.7, 115.4, 115.2, 55.6, 47.5, 31.6, 30.1, 28.9, 26.3, 22.5, 13.9, 9.1, 8.7.

Melting point: 81°C.

3-Dodecyl-1-(4-methoxyphenyl)-4,5-dimethyl-1*H*-imidazol-3-ium bromide (18)




Following the general procedure, 45 mmol of imidazole **3** were alkylated using 1-bromododecane. The product was obtained as a brown solid (19.3 g, 43 mmol, 95%).

¹H NMR: (300MHz, CDCl₃) δ 10.00 (s, 1 H), 7.34 - 7.42 (m, 2 H), 6.92 - 7.03 (m, 2 H), 4.33 - 4.44 (m, 2 H), 3.79 (s, 3 H), 2.27 (s, 3 H), 2.10 (s, 3 H), 1.75 - 1.92 (m, 2 H), 1.08 - 1.26 (m, 18 H), 0.77 - 0.85 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 160.8, 135.6, 127.0, 126.9, 126.3, 125.6, 115.3, 115.1, 55.6, 47.4, 31.7, 30.1, 29.4, 29.3, 29.2, 29.1, 28.9, 26.2, 22.5, 13.9, 9.1, 8.6.

Melting point: 88 °C.

1-(4-Bromophenyl)-3-butyl-4,5-dimethyl-1*H*-imidazol-3-ium bromide (19)




Following the general procedure, 55 mmol of imidazole **4** were alkylated using 1-bromobutane. The product was obtained as a brown solid (19.6 g, 50 mmol, 92%).

¹H NMR: (300MHz, CDCl₃) δ 10.21 (s, 1 H), 7.62 - 7.69 (m, 2 H), 7.42 - 7.50 (m, 2 H), 4.37 (t, *J* = 7.4 Hz, 2 H), 2.30 (s, 3 H), 2.15 (s, 3 H), 1.85 (quin, *J* = 7.6 Hz, 2 H), 1.40 (sxt, *J* = 7.4 Hz, 2 H), 0.92 (t, *J* = 7.4 Hz, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 135.8, 133.3, 132.0, 127.5, 126.9, 126.7, 124.8, 47.4, 31.8, 19.5, 13.4, 9.3, 8.7.

Melting point: 165 °C.

1-(4-Bromophenyl)-4,5-dimethyl-3-octyl-1*H*-imidazol-3-ium bromide (20)




Following the general procedure, 50 mmol of imidazole **4** were alkylated using 1-bromooctane. The product was obtained as a brown solid (20.4 g, 46 mmol, 92%).

¹H NMR: (300MHz, CDCl₃) δ 10.25 (s, 1 H), 7.64 - 7.71 (m, 2 H), 7.44 - 7.55 (m, 2 H), 4.38 (t, *J* = 7.7 Hz, 2 H), 2.30 (s, 3 H), 2.16 (s, 3 H), 1.88 (quin, *J* = 7.5 Hz, 2 H), 1.17 - 1.31 (m, 10 H), 0.77 - 0.88 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 136.0, 133.6, 133.4, 132.1, 127.5, 127.4, 126.9, 126.6, 124.5, 47.7, 31.6, 30.1, 28.9, 26.3, 22.5, 14.0, 9.3, 8.7.

Melting point: 107 °C.

1-(4-Bromophenyl)-3-dodecyl-4,5-dimethyl-1*H*-imidazol-3-ium bromide (21)




Following the general procedure, 45 mmol of imidazole **4** were alkylated using 1-bromododecane. The product was obtained as a brown solid (21.6 g, 43 mmol, 96%).

¹H NMR: (300MHz, CDCl₃) δ 10.26 (s, 1 H), 7.66 - 7.73 (m, 2 H), 7.47 - 7.56 (m, 2 H), 4.35 - 4.45 (m, 2 H), 2.32 (s, 3 H), 2.17 (s, 3 H), 1.83 - 1.98 (m, 2 H), 1.17 - 1.32 (m, 18 H), 0.81 - 0.90 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 136.1, 133.7, 133.5, 132.1, 127.5, 127.4, 126.9, 126.6, 125.0, 47.8, 31.8, 30.1, 29.5, 29.5, 29.4, 29.3, 29.1, 26.4, 22.6, 14.1, 9.3, 8.7.

Melting point: 84°C.

3-Butyl-4,5-dimethyl-1-(4-(trifluoromethyl)phenyl)-1*H*-imidazol-3-ium bromide (22)



Following the general procedure, 55 mmol of imidazole **5** were alkylated using 1-bromobutane. The product was obtained as a brown solid (17.7 g, 47 mmol, 85%).


¹H NMR: (300MHz, CDCl₃) δ 10.28 (s, 1 H), 7.76 (s, 4 H), 4.33 (t, *J* = 7.5 Hz, 2 H), 2.29 (s, 3 H), 2.16 (s, 3 H), 1.83 (quin, *J* = 7.6 Hz, 2 H), 1.38 (sxt, *J* = 7.5 Hz, 2 H), 0.88 (t, *J* = 7.3 Hz, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 135.9, 135.7, 132.3 (q, *J* = 33.4 Hz), 127.3, 127.2, 126.7, 126.5, 124.8, 47.3, 31.6, 19.4, 13.3, 9.3, 8.6.

¹⁹F NMR: (282 MHz, CDCl₃) δ -63.0.

Melting point: 95°C.

4,5-Dimethyl-3-octyl-1-(4-(trifluoromethyl)phenyl)-1*H*-imidazol-3-ium bromide (23)



Following the general procedure, 50 mmol of imidazole **5** were alkylated using 1-bromooctane. The product was obtained as a brown solid (20.4 g, 47 mmol, 94%).


¹H NMR: (300MHz, CDCl₃) δ 10.31 (s, 1 H), 7.78 (s, 4 H), 4.29 - 4.41 (m, 2 H), 2.30 (s, 3 H), 2.18 (s, 3 H), 1.87 (quin, *J* = 7.6 Hz, 2 H), 1.16 - 1.39 (m, 10 H), 0.73 - 0.85 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 135.9, 132.3 (q, *J* = 33.4 Hz), 127.4, 127.3, 127.2, 126.7, 126.5, 124.8, 47.7, 31.5, 29.9, 28.8, 26.2, 22.4, 13.8, 9.4, 8.7.

¹⁹F NMR: (282 MHz, CDCl₃) δ -63.0.

Melting point: 113°C.

3-Dodecyl-4,5-dimethyl-1-(4-(trifluoromethyl)phenyl)-1*H*-imidazol-3-ium bromide (24)



Following the general procedure, 45 mmol of imidazole **5** were alkylated using 1-bromododecane. The product was obtained as a brown solid (21.4 g, 44 mmol, 97%).


¹H NMR: (300MHz, CDCl₃) δ 10.21 (s, 1 H), 7.79 (s, 4 H), 4.35 (t, *J* = 7.6 Hz, 2 H), 2.31 (s, 3 H), 2.18 (s, 3 H), 1.75 - 1.98 (m, 2 H), 1.16 - 1.40 (m, 18 H), 0.76 - 0.86 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 136.0, 135.9, 132.3 (q, *J* = 33.4 Hz), 127.3, 127.2, 126.7, 126.6, 124.9, 47.7, 31.7, 30.0, 29.4, 29.4, 29.3, 29.1, 28.9, 26.3, 22.5, 20.0, 9.4, 8.7.

¹⁹F NMR: (282 MHz, CDCl₃) δ -63.0.

Melting point: 90°C.

3-Butyl-4,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1*H*-imidazol-3-ium bromide (25)



Following the general procedure, 55 mmol of imidazole **6** were alkylated using 1-bromobutane. The product was obtained as a brown solid (21.2 g, 54 mmol, 98%).


¹H NMR: (300MHz, CDCl₃) δ 10.16 (s, 1 H), 7.64-7.67 (m, 2 H), 7.34-7.37 (m, 2 H), 4.37 (t, *J* = 7.6 Hz, 2 H), 2.30 (s, 3 H), 2.15 (s, 3 H), 1.85 (quin, *J* = 7.6 Hz, 2 H), 1.39 (m, 2 H), 0.84 - 0.98 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 150.2, 135.8, 131.3, 127.8, 127.0, 126.8, 122.2, 120.0 (q, *J* = 258.7 Hz), 47.3, 31.8, 19.4, 13.4, 9.3, 8.7.

¹⁹F NMR: (282 MHz, CDCl₃) δ -57.9.

Melting point: 66°C.

4,5-Dimethyl-3-octyl-1-(4-(trifluoromethoxy)phenyl)-1*H*-imidazol-3-ium bromide (26)



Following the general procedure, 50 mmol of imidazole **6** were alkylated using 1-bromooctane. The product was obtained as a brown solid (22 g, 49 mmol, 98%).


¹H NMR: (300MHz, CDCl₃) δ 10.17 (s, 1 H), 7.62 - 7.72 (m, 2 H), 7.34 - 7.41 (m, 2 H), 4.37 (t, *J* = 7.4 Hz, 2 H), 2.30 (s, 3 H), 2.16 (s, 3 H), 1.79 - 1.94 (m, 2 H), 1.17 - 1.41 (m, 10 H), 0.73 - 0.86 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 150.2, 135.9, 131.3, 127.8, 127.0, 126.8, 122.3, 120.0 (q, *J* = 258.7 Hz), 47.6, 31.5, 30.0, 28.9, 26.2, 22.4, 13.9, 9.3, 8.7.

¹⁹F NMR: (282 MHz, CDCl₃) δ -57.9.

Melting point: 107°C.

3-Dodecyl-4,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1*H*-imidazol-3-ium bromide (27)



Following the general procedure, 45 mmol of imidazole **6** were alkylated using 1-bromododecane. The product was obtained as a brown solid (18.5 g, 37 mmol, 81%).


¹H NMR: (300MHz, CDCl₃) δ 10.16 (s, 1 H), 7.63 - 7.68 (m, 2 H), 7.32 - 7.42 (m, 2 H), 4.30 - 4.42 (m, 2 H), 2.30 (s, 3 H), 2.16 (s, 3 H), 1.80 - 1.93 (m, 2 H), 1.19 - 1.31 (m, 18 H), 0.75 - 0.87 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 150.2, 135.9, 131.3, 127.8, 127.0, 126.8, 122.3, 120.0 (q, *J* = 258.7 Hz), 47.6, 31.7, 30.0, 29.4, 29.4, 29.3, 29.1, 29.0, 26.3, 22.5, 13.4, 9.3, 8.7.

¹⁹F NMR: (282 MHz, CDCl₃) δ -57.9.

Melting point: 79°C.

3-Butyl-4,5-dimethyl-1-(*o*-tolyl)-1*H*-imidazol-3-ium bromide (28)




Following the general procedure, 54 mmol of imidazole **7** were alkylated using 1-bromobutane. The product was obtained as a brown solidified melt (15.2 g, 47 mmol, 87%).

^1H NMR: (300MHz, CDCl_3) δ 10.06 (s, 1 H), 7.27 - 7.49 (m, 4 H), 4.55 (t, $J = 7.4$ Hz, 2 H), 2.34 (s, 3 H), 2.12 (s, 3 H), 1.99 (s, 3 H), 1.86 (m, 2 H), 1.37 - 1.52 (m, 2 H), 0.96 (t, $J = 7.3$ Hz, 3 H).

^{13}C NMR: (75 MHz, CDCl_3) δ 136.1, 134.8, 132.0, 131.8, 131.2, 127.7, 127.3, 127.3, 126.4, 47.4, 32.1, 19.5, 17.5, 13.6, 8.8, 8.6.

Melting point: solidified melt.

4,5-Dimethyl-3-octyl-1-(*o*-tolyl)-1*H*-imidazol-3-ium bromide (29)




Following the general procedure, 54 mmol of imidazole **7** were alkylated using 1-bromooctane. The product was obtained as a brown solidified melt (18.3 g, 48 mmol, 90%).

^1H NMR: (300MHz, CDCl_3) δ 10.04 (s, 1 H), 7.27 - 7.49 (m, 4 H), 4.53 (t, $J = 7.6$ Hz, 2 H), 2.33 (s, 3 H), 2.11 (s, 3 H), 1.99 (s, 3 H), 1.87 (quin, $J = 7.4$ Hz, 2 H), 1.17 - 1.43 (m, 10 H), 0.78 - 0.88 (m, 3 H).

^{13}C NMR: (75 MHz, CDCl_3) δ 136.0, 134.8, 132.0, 131.8, 131.2, 127.7, 127.3, 126.4, 47.6, 31.6, 30.2, 29.0, 26.2, 22.5, 17.5, 14.0, 8.8, 8.6.

Melting point: solidified melt.

3-Dodecyl-4,5-dimethyl-1-(*o*-tolyl)-1*H*-imidazol-3-ium bromide (30)




Following the general procedure, 48 mmol of imidazole **7** were alkylated using 1-bromododecane. The product was obtained as a brown solid (18.4 g, 42 mmol, 87%).

¹H NMR: (300MHz, CDCl₃) δ 10.07 (s, 1 H), 7.27 - 7.50 (m, 4 H), 4.50 - 4.59 (m, 2 H), 2.34 (s, 3 H), 2.12 (s, 3 H), 1.99 (s, 3 H), 1.82 - 1.94 (m, 2 H), 1.20 - 1.33 (m, 18 H), 0.80 - 0.90 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 136.2, 134.8, 132.1, 131.8, 131.2, 127.7, 127.4, 127.2, 126.4, 47.6, 31.8, 30.2, 29.5, 29.5, 29.4, 29.3, 29.1, 26.2, 22.6, 17.5, 14.0, 8.8, 8.6.

Melting point: 54°C.

3-Butyl-1-(2-methoxyphenyl)-4,5-dimethyl-1*H*-imidazol-3-ium bromide (31)




Following the general procedure, 50 mmol of imidazole **8** were alkylated using 1-bromobutane. The product was obtained as a brown solid (12.5 g, 37 mmol, 74%).

¹H NMR: (300MHz, CDCl₃) δ 9.77 (s, 1 H), 7.29 - 7.49 (m, 2 H), 6.95 - 7.04 (m, 2 H), 4.43 (t, *J* = 7.4 Hz, 2 H), 3.75 (s, 3 H), 2.27 (s, 3 H), 1.95 (s, 3 H), 1.71 - 1.87 (m, 2 H), 1.30 - 1.47 (m, 2 H), 0.88 (t, *J* = 7.4 Hz, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 153.5, 135.8, 132.3, 128.1, 128.0, 125.7, 121.3, 121.2, 112.2, 55.8, 47.0, 31.8, 19.2, 13.4, 8.6, 8.5.

Melting Point: 133°C.

1-(2-Methoxyphenyl)-4,5-dimethyl-3-octyl-1*H*-imidazol-3-ium bromide (32)




Following the general procedure, 35 mmol of imidazole **8** were alkylated using 1-bromooctane. The product was obtained as a brown solidified melt (13.7 g, 34 mmol, 99%).

¹H NMR: (300MHz, CDCl₃) δ 9.85 (s, 1 H), 7.37 - 7.52 (m, 2 H), 7.01 - 7.11 (m, 2 H), 4.47 (t, *J* = 7.6 Hz, 2 H), 3.80 (s, 3 H), 2.30 (s, 3 H), 1.99 (s, 3 H), 1.77 - 1.92 (m, 2 H), 1.11 - 1.36 (m, 10 H), 0.79 - 0.84 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 153.7, 136.2, 132.4, 128.3, 128.1, 125.7, 121.5, 121.4, 112.3, 55.9, 47.5, 31.6, 30.1, 29.0, 26.1, 22.4, 13.9, 8.6, 8.6.

Melting point: solidified melt.

3-Dodecyl-1-(2-methoxyphenyl)-4,5-dimethyl-1*H*-imidazol-3-ium bromide (33)




Following the general procedure, 25 mmol of imidazole **8** were alkylated using 1-bromododecane. The product was obtained as a brown solidified melt (9.7 g, 22 mmol, 86%).

¹H NMR: (300MHz, CDCl₃) δ 9.89 (s, 1 H), 7.40 - 7.55 (m, 2 H), 7.02 - 7.15 (m, 2 H), 4.49 (t, *J* = 7.6 Hz, 2 H), 3.82 (s, 3 H), 2.31 (s, 3 H), 2.01 (s, 3 H), 1.81 - 1.94 (m, 2 H), 1.18 - 1.37 (m, 18 H), 0.81 - 0.87 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 153.7, 136.4, 132.5, 128.4, 128.1, 125.7, 121.6, 121.5, 112.3, 56.0, 47.5, 31.8, 30.2, 29.5, 29.5, 29.4, 29.2, 29.1, 26.2, 22.6, 14.0, 8.7, 8.6.

Melting point: solidified melt.

3-Butyl-1-(2,4-difluorophenyl)-4,5-dimethyl-1*H*-imidazol-3-ium bromide (34)



Following the general procedure, 50 mmol of imidazole **9** were alkylated using 1-bromobutane. The product was obtained as a brown solidified melt (17 g, 49 mmol, 98%).


¹H NMR: (300MHz, CDCl₃) δ 10.15 (s, 1 H), 7.79 - 7.92 (m, 1 H), 6.95 - 7.13 (m, 2 H), 4.37 (t, *J* = 7.6 Hz, 2 H), 2.30 (s, 3 H), 2.05 (s, 3 H), 1.85 (quin, *J* = 7.6 Hz, 2 H), 1.31 - 1.46 (m, 2 H), 0.91 (t, *J* = 7.3 Hz, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 165.6 (dd, *J* = 267.0, 10.7 Hz), 158.3 (dd, *J* = 268.8, 13.1 Hz), 136.6, 130.7 (d, *J* = 10.7 Hz), 127.9, 126.6, 117.2, 113.4 (dd, *J* = 26.8, 3.6 Hz), 105.8 (dd, *J* = 49.5, 22.7 Hz), 47.5, 31.6, 19.4, 13.3, 8.6, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -102.8, -116.4.

Melting point: solidified melt.

1-(2,4-Difluorophenyl)-4,5-dimethyl-3-octyl-1*H*-imidazol-3-ium bromide (35)



Following the general procedure, 43 mmol of imidazole **9** were alkylated using 1-bromooctane. The product was obtained as a brown solid (14.4 g, 36 mmol, 84%).


¹H NMR: (300MHz, CDCl₃) δ 10.15 (s, 1 H), 7.90 - 8.01 (m, 1 H), 6.99 - 7.15 (m, 2 H), 4.40 (t, *J* = 7.6 Hz, 2 H), 2.32 (s, 3 H), 2.09 (s, 3 H), 1.84 - 1.97 (m, 2 H), 1.14 - 1.36 (m, 10 H), 0.78 - 0.87 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 165.7 (dd, *J* = 267.0, 10.7 Hz), 158.4 (dd, *J* = 268.8, 13.1 Hz), 136.8, 130.9 (d, *J* = 10.1 Hz), 127.9, 126.5, 117.2, 113.6 (dd, *J* = 26.8, 3.6 Hz), 105.8 (dd, *J* = 50.1, 22.7 Hz), 47.9, 31.6, 29.9, 28.9, 26.2, 22.5, 19.9, 8.7, 8.6.

¹⁹F NMR: (282 MHz, CDCl₃) δ -102.7, -116.5.

Melting point: 57 °C.

1-(2,4-Difluorophenyl)-3-dodecyl-4,5-dimethyl-1*H*-imidazol-3-ium bromide (36)



Following the general procedure, 38 mmol of imidazole **9** were alkylated using 1-bromododecane. The product was obtained as a brown solid (12.7 g, 28 mmol, 73%).

¹H NMR: (300MHz, CDCl₃) δ 10.16 (s, 1 H), 7.89 - 8.01 (m, 1 H), 6.98 - 7.15 (m, 2 H), 4.39 (t, *J* = 7.4 Hz, 2 H), 2.32 (s, 3 H), 2.09 (s, 3 H), 1.83 - 1.96 (m, 2 H), 1.18 - 1.33 (m, 18 H), 0.79 - 0.86 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 165.7 (dd, *J* = 267.0, 10.7 Hz), 158.4 (dd, *J* = 268.8, 13.1 Hz), 136.8, 130.9 (d, *J* = 10.1 Hz), 127.9, 126.5, 117.2, 113.6 (dd, *J* = 26.8, 3.6 Hz), 105.8 (dd, *J* = 49.5, 22.7 Hz), 47.9, 31.8, 29.9, 29.5, 29.4, 29.3, 29.2, 29.0, 26.2, 22.5, 14.0, 8.7, 8.6 (d, *J* = 3 Hz).

¹⁹F NMR: (282 MHz, CDCl₃) δ -102.7, -116.5.


Melting point: 69 °C.

S3 Synthesis of NTf₂ ionic liquids

General procedure for the anion exchange

In a round bottom flask, the corresponding bromide salt (1 equiv) was dissolved in a small amount of methanol. LiNTf₂ (1.1 equiv 70% aq. solution), additional water and DCM were added and the reaction mixture was stirred at room temperature for 24 h. The organic phase was separated and the water was extracted with DCM. The combined organic phases were washed three times with water and dried over MgSO₄. The solvent was removed under reduced pressure to yield the corresponding ionic liquid.

3-Butyl-4,5-dimethyl-1-phenyl-1*H*-imidazol-3-ium bis(trifluoromethylsulfonyl)amide (37)



Following the general procedure, 16 mmol of bromide salt **10** were used for the anion exchange. The product was obtained as a dark green oil (7 g, 14 mmol, 85%).

¹H NMR: (300MHz, CDCl₃) δ 8.57 (s, 1 H), 7.52 - 7.62 (m, 3 H), 7.38 - 7.45 (m, 2 H), 4.10 - 4.21 (m, 2 H), 2.34 (s, 3 H), 2.16 (s, 3 H), 1.78 - 1.93 (m, 2 H), 1.43 (sxt, *J* = 7.5 Hz, 2 H), 0.99 (t, *J* = 7.4 Hz, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 133.6, 133.0, 130.1, 130.3, 128.0, 127.4, 125.9, 119.9 (q, *J* = 321.5 Hz), 47.5, 31.5, 19.6, 13.3, 9.0, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.6.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 40.08%, H: 4.15%, N: 8.25%, S: 12.59%.

Found: C: 40.41%, H: 4.29%, N: 7.82%, S: 12.43%.

4,5-Dimethyl-3-octyl-1-phenyl-1*H*-imidazol-3-ium bis(trifluoromethylsulfonyl)amide (38)



Following the general procedure, 14 mmol of bromide salt **11** were used for the anion exchange. The product was obtained as a dark green oil (7 g, 12 mmol, 89%).

¹H NMR: (300MHz, CDCl₃) δ 8.56 (s, 1 H), 7.55 - 7.63 (m, 3 H), 7.38 - 7.47 (m, 2 H), 4.15 (t, *J* = 7.7 Hz, 2 H), 2.34 (s, 3 H), 2.16 (s, 3 H), 1.80 - 1.93 (m, 2 H), 1.22 - 1.41 (m, 10 H), 0.83 - 0.92 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 133.6, 133.0, 131.0, 130.3, 128.0, 127.3, 126.0, 119.9 (q, *J* = 321.5 Hz), 47.7, 31.6, 29.6, 29.0, 28.9, 26.3, 22.5, 14.0, 9.0, 8.6.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.6.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 44.60%, H: 5.17%, N: 7.43%, S: 11.34%.

Found: C: 44.54%, H: 5.42%, N: 7.41%, S: 11.20%.

3-Dodecyl-4,5-dimethyl-1-phenyl-1*H*-imidazol-3-ium bis(trifluoromethylsulfonyl)amide (39)



Following the general procedure, 12 mmol of bromide salt **12** were used for the anion exchange. The product was obtained as a light green oil (6.6 g, 11 mmol, 88%).

¹H NMR: (300MHz, CDCl₃) δ 8.56 (s, 1 H) 7.54 - 7.62 (m, 3 H) 7.38 - 7.47 (m, 2 H) 4.15 (t, *J* = 7.7 Hz, 2 H) 2.34 (s, 3 H) 2.16 (s, 3 H) 1.81 - 1.93 (m, 2 H) 1.18 - 1.35 (m, 18 H) 0.81 - 0.93 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 133.7, 133.0, 131.0, 130.3, 128.0, 127.3, 126.0, 119.9 (q, *J* = 321.5 Hz), 47.8, 31.9, 29.6, 29.6, 29.5, 29.3, 29.3, 29.0, 26.3, 22.7, 14.1, 9.1, 8.6.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.6.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 48.30%, H: 6.00%, N: 6.76%, S: 10.31%.

Found: C: 48.11%, H: 6.36%, N: 6.94%, S: 10.22%.

3-Butyl-4,5-dimethyl-1-(*p*-tolyl)-1*H*-imidazol-3-ium bis(trifluoromethylsulfonyl)amide (40)



Following the general procedure, 16 mmol of bromide salt **13** were used for the anion exchange. The product was obtained as a dark brown oil (7.5 g, 14 mmol, 89%).

¹H NMR: (300MHz, CDCl₃) δ 8.51 (s, 1 H), 7.33 - 7.38 (m, 2 H), 7.27 (d, *J* = 7.7 Hz, 2 H), 4.07 - 4.20 (m, 2 H), 2.44 (s, 3 H), 2.33 (s, 3 H), 2.14 (s, 3 H), 1.76 - 1.91 (m, 2 H), 1.43 (sxt, *J* = 7.4 Hz, 2 H), 0.98 (t, *J* = 7.3 Hz, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 141.4, 133.5, 130.8, 130.4, 128.1, 127.2, 125.6, 119.9 (q, *J* = 321.5 Hz), 47.4, 31.5, 21.2, 20.0, 13.3, 9.0, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.6.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 41.30%, H: 4.43%, N: 8.03%, S: 12.25%.

Found: C: 41.63%, H: 4.62%, N: 7.68%, S: 11.99%.

4,5-Dimethyl-3-octyl-1-(*p*-tolyl)-1*H*-imidazol-3-ium bis(trifluoromethylsulfonyl)amide (41)



Following the general procedure, 13 mmol of bromide salt **14** were used for the anion exchange. The product was obtained as a dark brown oil (7.2 g, 12 mmol, 94%).

¹H NMR: (300MHz, CDCl₃) δ 8.50 (s, 1 H), 7.33 - 7.39 (m, 2 H), 7.27 (d, *J* = 8.8 Hz, 2 H), 4.13 (t, *J* = 7.0 Hz, 2 H), 2.44 (s, 3 H), 2.33 (s, 3 H), 2.14 (s, 3 H), 1.81 - 1.92 (m, 2 H), 1.22 - 1.37 (m, 10 H), 0.84 - 0.90 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 141.4, 133.6, 130.1, 130.4, 128.1, 127.2, 125.7, 119.9 (q, *J* = 321.9 Hz), 47.7, 29.6, 29.0, 28.9, 26.3, 22.5, 21.2, 14.0, 9.0, 8.6.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.6.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 45.59%, H: 5.39%, N: 7.25%, S: 11.06%.

Found: C: 45.89%, H: 5.66%, N: 6.97%, S: 10.96%.

3-Dodecyl-4,5-dimethyl-1-(*p*-tolyl)-1*H*-imidazol-3-ium bis(trifluoromethylsulfonyl)amide (42)



Following the general procedure, 12 mmol of bromide salt **15** were used for the anion exchange. The product was obtained as a dark brown oil (6.7 g, 11 mmol, 92%).

^1H NMR: (300MHz, CDCl_3) δ 8.51 (s, 1 H), 7.33 - 7.39 (m, 2 H), 7.28 (d, J = 9.4 Hz, 2 H), 4.14 (t, J = 7.7 Hz, 2 H), 2.44 (s, 3 H), 2.33 (s, 3 H), 2.14 (s, 3 H), 1.79 - 1.93 (m, 2 H), 1.18 - 1.35 (m, 18 H), 0.82 - 0.91 (m, 3 H).

^{13}C NMR: (75 MHz, CDCl_3) δ 141.4, 133.6, 130.8, 130.4, 128.0, 127.2, 125.6, 119.9 (q, J = 321.9 Hz), 47.7, 31.9, 29.6, 29.6, 29.5, 29.3, 29.3, 28.9, 26.3, 22.6, 21.2, 14.1, 9.0, 8.6.

^{19}F NMR: (282 MHz, CDCl_3) δ -79.6.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 49.12%, H: 6.18%, N: 6.61%, S: 10.09%.

Found: C: 49.34%, H: 6.35%, N: 6.21%, S: 10.02%.

3-Butyl-1-(4-methoxyphenyl)-4,5-dimethyl-1*H*-imidazol-3-ium bis(trifluoromethylsulfonyl)amide (43)



Following the general procedure, 18 mmol of bromide salt **16** were used for the anion exchange. The product was obtained as a dark brown oil (8.9 g, 16 mmol, 93%).

^1H NMR: (300MHz, CDCl_3) δ 8.47 (s, 1 H), 7.30 – 7.33 (m, 2 H), 7.01 – 7.04 (m, 2 H), 4.12 (t, J = 7.7 Hz, 2 H), 3.86 (s, 3 H), 2.32 (s, 3 H), 2.12 (s, 3 H), 1.84 (quin, J = 7.6 Hz, 2 H), 1.42 (sxt, J = 7.4 Hz, 2 H), 0.98 (t, J = 7.3 Hz, 3 H).

^{13}C NMR: (75 MHz, CDCl_3) δ 161.2, 133.6, 128.3, 127.3, 127.1, 125.5, 119.9 (q, J = 321.9 Hz), 115.3, 55.7, 47.4, 31.4, 19.5, 13.3, 8.9, 8.5.

^{19}F NMR: (282 MHz, CDCl_3) δ -79.6.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 40.07%, H: 4.30%, N: 7.79%, S: 11.88%.

Found: C: 39.95%, H: 4.68%, N: 7.50%, S: 11.74%.

**1-(4-Methoxyphenyl)-4,5-dimethyl-3-octyl-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (44)**



Following the general procedure, 13 mmol of bromide salt **17** were used for the anion exchange. The product was obtained as a dark brown oil (6.3 g, 11 mmol, 80%).

¹H NMR: (300MHz, CDCl₃) δ 8.48 (s, 1 H), 7.29 - 7.36 (m, 2 H), 6.99 - 7.07 (m, 2 H), 4.13 (t, *J* = 7.4 Hz, 2 H), 3.86 (s, 3 H), 2.32 (s, 3 H), 2.13 (s, 3 H), 1.81 - 1.91 (m, 2 H), 1.24 - 1.38 (m, 10 H), 0.83 - 0.90 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 161.2, 133.6, 128.3, 127.3, 127.1, 125.5, 119.9 (q, *J* = 321.3 Hz), 115.3, 55.7, 47.6, 31.6, 29.6, 29.0, 28.9, 26.3, 22.5, 14.0, 8.9, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.6.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 44.36%, H: 5.25%, N: 7.06%, S: 10.77%.

Found: C: 44.27%, H: 5.54%, N: 7.03%, S: 10.69%.

**3-Dodecyl-1-(4-methoxyphenyl)-4,5-dimethyl-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (45)**



Following the general procedure, 11 mmol of bromide salt **18** were used for the anion exchange. The product was obtained as a dark orange oil (6.5 g, 10 mmol, 89%).

¹H NMR: (300MHz, CDCl₃) δ 8.44 (s, 1 H), 7.28 - 7.35 (m, 2 H), 6.99 - 7.06 (m, 2 H), 4.05 - 4.16 (m, 2 H), 3.85 (s, 3 H), 2.30 (s, 3 H), 2.11 (s, 3 H), 1.84 (quin, *J* = 7.5 Hz, 2 H), 1.16 - 1.44 (m, 18 H), 0.82 - 0.90 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 161.2, 133.8, 128.3, 127.3, 126.1, 125.5, 119.9 (q, *J* = 321.3 Hz), 115.2, 55.7, 47.5, 31.8, 29.5, 29.4, 29.3, 29.3, 28.9, 26.3, 22.6, 14.0, 8.9, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.6.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 47.92%, H: 6.03%, N: 6.45%, S: 9.84%.

Found: C: 48.09%, H: 6.18%, N: 6.30%, S: 9.90%.

**1-(4-Bromophenyl)-3-butyl-4,5-dimethyl-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (46)**



Following the general procedure, 13 mmol of bromide salt **19** were used for the anion exchange. The product was obtained as a dark brown oil (7.2 g, 12 mmol, 95%).

¹H NMR: (300MHz, CDCl₃) δ 8.55 (s, 1 H), 7.66 - 7.75 (m, 2 H), 7.29 - 7.39 (m, 2 H), 4.13 (t, *J* = 7.7 Hz, 2 H), 2.32 (s, 3 H), 2.15 (s, 3 H), 1.78 - 1.91 (m, 2 H), 1.43 (sxt, *J* = 7.4 Hz, 2 H), 0.98 (t, *J* = 7.3 Hz, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 133.7, 133.5, 132.0, 128.0, 127.7, 127.6, 125.3, 119.9 (q, *J* = 321.3 Hz), 47.6, 31.4, 19.6, 13.3, 9.0, 8.6.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.6.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 34.70%, H: 3.43%, N: 7.14%, S: 10.90%.

Found: C: 34.56%, H: 3.43%, N: 7.52%, S: 10.75%.

**1-(4-Bromophenyl)-4,5-dimethyl-3-octyl-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (47)**



Following the general procedure, 11 mmol of bromide salt **20** were used for the anion exchange. The product was obtained as a dark brown oil (7.0 g, 10 mmol, 96%).

¹H NMR: (300MHz, CDCl₃) δ 8.56 (s, 1 H), 7.65 - 7.72 (m, 2 H), 7.29 - 7.36 (m, 2 H), 4.04 - 4.14 (m, 2 H), 2.33 (s, 3 H), 2.15 (s, 3 H), 1.78 - 1.91 (m, 2 H), 1.18 - 1.44 (m, 10 H), 0.81 - 0.90 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 133.9, 133.7, 133.5, 132.0, 128.0, 127.7, 125.4, 119.9 (q, *J* = 321.3 Hz), 48.0, 31.9, 29.6, 29.3, 28.9, 26.3, 22.6, 14.0, 9.2, 8.7.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.6.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 39.14%, H: 4.38%, N: 6.52%, S: 9.95%.

Found: C: 38.73%, H: 4.47%, N: 6.93%, S: 9.78%.

**1-(4-Bromophenyl)-3-dodecyl-4,5-dimethyl-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (48)**



Following the general procedure, 10 mmol of bromide salt **21** were used for the anion exchange. The product was obtained as an orange solid. (6.9 g, 10 mmol, 99%).

¹H NMR: (300MHz, CDCl₃) δ 8.55 (s, 1 H), 7.65 - 7.73 (m, 2 H), 7.29 - 7.37 (m, 2 H), 4.04 - 4.18 (m, 2 H), 2.33 (s, 3 H), 2.15 (s, 3 H), 1.79 - 1.91 (m, 2 H), 1.20 - 1.37 (m, 18 H), 0.82 - 0.92 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 133.8, 133.7, 133.5, 132.0, 128.0, 127.7, 125.4, 119.9 (q, *J* = 321.3 Hz), 41.8, 31.8, 29.5, 29.5, 29.4, 29.3, 29.3, 28.9, 26.3, 22.6, 14.1, 8.9, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.6.


Melting point: 27 °C.

Elemental analysis:

Calculated: C: 42.86%, H: 5.18%, N: 6.00%, S: 9.15%.

Found: C: 43.22%, H: 5.36%, N: 5.63%, S: 9.16%.

**3-Butyl-4,5-dimethyl-1-(4-(trifluoromethyl)phenyl)-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (49)**



Following the general procedure, 13mmol of bromide salt **22** were used for the anion exchange. The product was obtained as an orange oil. (6.7 g, 12 mmol, 87%).

¹H NMR: (300MHz, CDCl₃) δ 8.62 (s, 1 H), 7.81 - 7.89 (m, 2 H), 7.59 - 7.66 (m, 2 H), 4.07 - 4.23 (m, 2 H), 2.34 (s, 3 H), 2.17 (s, 3 H), 1.79 - 1.92 (m, 2 H), 1.43 (sxt, *J* = 7.5 Hz, 2 H), 0.98 (t, *J* = 7.3 Hz, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 135.9, 133.8, 133.3, 132.8, 127.9, 127.5, 127.4, 126.8, 119.9 (q, *J* = 321.3 Hz), 47.7, 31.3, 19.5, 13.3, 9.0, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -63.7, -79.7.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 37.44%, H: 3.49%, N: 7.28%, S: 11.10%.

Found: C: 37.57%, H: 3.71%, N: 7.00%, S: 11.09%.

**4,5-Dimethyl-3-octyl-1-(4-(trifluoromethyl)phenyl)-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (50)**



Following the general procedure, 12 mmol of bromide salt **23** were used for the anion exchange. The product was obtained as an orange oil. (7.2 g, 11 mmol, 98%).

¹H NMR: (300MHz, CDCl₃) δ 8.62 (s, 1 H), 7.85 (d, *J* = 8.5 Hz, 2 H), 7.62 (d, *J* = 8.3 Hz, 2 H), 4.09 - 4.20 (m, 2 H), 2.34 (s, 3 H), 2.17 (s, 3 H), 1.81 - 1.95 (m, 2 H), 1.18 - 1.47 (m, 10 H), 0.82 - 0.93 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 135.9, 133.8, 133.3, 132.9, 127.9, 127.5, 127.4, 126.8, 119.9 (q, *J* = 321.3 Hz), 47.9, 31.6, 29.5, 28.9, 28.8, 26.3, 22.5, 14.0, 9.1, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -63.7, -79.7.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 41.71%, H: 4.45%, N: 6.63%, S: 10.12%.

Found: C: 41.91%, H: 4.60%, N: 6.29%, S: 10.06%.

**3-Dodecyl-4,5-dimethyl-1-(4-(trifluoromethyl)phenyl)-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (51)**



Following the general procedure, 10 mmol of bromide salt **24** were used for the anion exchange. The product was obtained as an orange solid. (6.8 g, 9 mmol, 95%).

¹H NMR: (300MHz, CDCl₃) δ 8.59 (s, 1 H), 7.84 (d, *J* = 8.3 Hz, 2 H), 7.62 (d, *J* = 8.8 Hz, 2 H), 4.07 - 4.17 (m, 2 H), 2.33 (s, 3 H), 2.17 (s, 3 H), 1.80 - 1.94 (m, 2 H), 1.21 - 1.43 (m, 18 H), 0.81 - 0.93 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 135.9, 133.6, 133.3, 132.9, 127.9, 127.5, 127.4, 126.8, 119.9 (q, *J* = 321.9 Hz), 47.9, 31.9, 29.5, 29.4, 29.3, 29.3, 28.9, 26.3, 22.6, 14.0, 9.0, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -63.7, -79.7.


Melting point: 40 °C.

Elemental analysis:

Calculated: C: 45.28%, H: 5.26%, N: 6.09%, S: 9.30%.

Found: C: 45.37%, H: 5.32%, N: 5.66%, S: 9.34%.

**3-Butyl-4,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (52)**



Following the general procedure, 13 mmol of bromide salt **25** were used for the anion exchange. The product was obtained as a light-yellow oil. (7.4 g, 12 mmol, 97%).

¹H NMR: (300MHz, CDCl₃) δ 8.57 (s, 1 H), 7.37 - 7.57 (m, 4 H), 4.13 (t, *J* = 7.7 Hz, 2 H), 2.33 (s, 3 H), 2.15 (s, 3 H), 1.85 (quin, *J* = 7.6 Hz, 2 H), 1.43 (sxt, *J* = 7.4 Hz, 2 H), 0.98 (t, *J* = 7.3 Hz, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 150.7, 133.8, 131.2, 128.1, 128.0, 127.6, 122.4, 118.5, 119.9 (q, *J* = 321.9 Hz), 47.6, 31.3, 19.6, 13.3, 9.0, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -58.6, -79.7.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 36.43%, H: 3.40%, N: 7.08%, S: 10.80%.

Found: C: 36.46%, H: 3.62%, N: 6.84%, S: 10.84%.

**4,5-Dimethyl-3-octyl-1-(4-(trifluoromethoxy)phenyl)-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (53)**



Following the general procedure, 11 mmol of bromide salt **26** were used for the anion exchange. The product was obtained as a light-yellow oil. (6.8 g, 10 mmol, 93%).

¹H NMR: (300MHz, CDCl₃) δ 8.56 (s, 1 H), 7.37 - 7.57 (m, 4 H), 4.04 - 4.21 (m, 2 H), 2.33 (s, 3 H), 2.16 (s, 3 H), 1.78 - 1.97 (m, 2 H), 1.21 - 1.44 (m, 10 H), 0.81 - 0.94 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 150.7, 133.7, 131.2, 128.1, 128.0, 127.6, 122.4, 118.5, 119.9 (q, *J* = 321.9 Hz), 47.8, 31.6, 29.5, 28.9, 28.8, 26.3, 22.5, 14.0, 9.0, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -58.6, -79.7.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 40.68%, H: 4.34%, N: 6.47%, S: 9.87%.

Found: C: 40.44%, H: 4.74%, N: 6.38%, S: 9.91%.

**3-Dodecyl-4,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (54)**



Following the general procedure, 10 mmol of bromide salt **27** were used for the anion exchange. The product was obtained as a light-yellow solid. (6.9 g, 10 mmol, 98%).

¹H NMR: (300MHz, CDCl₃) δ 8.56 (s, 1 H), 7.38 - 7.55 (m, 4 H), 4.07 - 4.16 (m, 2 H), 2.33 (s, 3 H), 2.15 (s, 3 H), 1.80 - 1.93 (m, 2 H), 1.21 - 1.44 (m, 18 H), 0.83 - 0.91 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 150.7, 133.7, 131.2, 128.1, 128.0, 127.6, 122.4, 118.5, 119.9 (q, *J* = 321.9 Hz), 47.8, 31.9, 29.6, 29.5, 29.4, 29.3, 28.9, 26.3, 22.6, 14.0, 8.9, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -58.6, -79.7.


Melting point: 38 °C.

Elemental analysis:

Calculated: C: 44.25%, H: 5.14%, N: 5.95%, S: 9.09%.

Found: C: 44.62%, H: 5.14%, N: 5.54%, S: 8.95%.

3-Butyl-4,5-dimethyl-1-(*o*-tolyl)-1*H*-imidazol-3-ium bis(trifluoromethylsulfonyl)amide (55)



Following the general procedure, 15 mmol of bromide salt **28** were used for the anion exchange. The product was obtained as a light-red oil. (6.3 g, 12 mmol, 80%).

¹H NMR: (600MHz, CDCl₃) δ 8.50 (s, 1 H), 7.49 - 7.54 (m, 1 H), 7.37 - 7.44 (m, 2 H), 7.30 (d, *J* = 8.1 Hz, 1 H), 4.19 (t, *J* = 7.7 Hz, 2 H), 2.38 (s, 3 H), 2.09 (s, 3 H), 2.03 (s, 3 H), 1.87 (quin, *J* = 7.6 Hz, 2 H), 1.44 (sxt, *J* = 7.5 Hz, 2 H), 1.00 (t, *J* = 7.5 Hz, 3 H).

¹³C NMR: (151 MHz, CDCl₃) δ 134.7, 133.5, 131.9, 131.6, 131.3, 128.3, 127.6, 127.3, 127.2, 119.7 (q, *J* = 321.4 Hz), 47.4, 31.3, 19.4, 16.8, 13.2, 8.4, 8.4.

¹⁹F NMR: (565 MHz, CDCl₃) δ -79.1.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 41.30%, H: 4.43%, N: 8.03%, S: 12.25%.

Found: C: 41.65%, H: 4.47%, N: 7.61%, S: 12.16%.

4,5-Dimethyl-3-octyl-1-(*o*-tolyl)-1*H*-imidazol-3-ium bis(trifluoromethylsulfonyl)amide (56)



Following the general procedure, 14 mmol of bromide salt **29** were used for the anion exchange. The product was obtained as a light-red oil. (5.4 g, 9 mmol, 67%).

¹H NMR: (600MHz, CDCl₃) δ 8.48 (s, 1 H), 7.47 - 7.51 (m, 1 H), 7.35 - 7.42 (m, 2 H), 7.26 - 7.29 (m, 1 H), 4.16 (t, *J* = 7.7 Hz, 2 H), 2.35 (s, 3 H), 2.07 (s, 3 H), 2.01 (s, 3 H), 1.86 (quin, *J* = 7.4 Hz, 2 H), 1.22 - 1.41 (m, 10 H), 0.87 (t, *J* = 7.0 Hz, 3 H).

¹³C NMR: (151 MHz, CDCl₃) δ 134.7, 133.5, 131.9, 131.6, 131.3, 128.4, 127.6, 127.3, 127.2, 119.7 (q, *J* = 321.4 Hz), 47.6, 31.5, 29.4, 28.9, 28.7, 26.1, 22.4, 16.8, 13.9, 8.4, 8.4.

¹⁹F NMR: (565 MHz, CDCl₃) δ -79.1.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 45.59%, H: 5.39%, N: 7.25%, S: 11.06%.

Found: C: 45.88%, H: 5.09%, N: 6.83%, S: 11.00%.

3-Dodecyl-4,5-dimethyl-1-(*o*-tolyl)-1*H*-imidazol-3-ium bis(trifluoromethylsulfonyl)amide (57)



Following the general procedure, 13 mmol of bromide salt **30** were used for the anion exchange. The product was obtained as a light-red oil. (6.4 g, 10 mmol, 77%).

¹H NMR: (600MHz, CDCl₃) δ 8.51 (s, 1 H), 7.50 - 7.54 (m, 1 H), 7.38 - 7.45 (m, 2 H), 7.29 - 7.33 (m, 1 H), 4.19 (t, *J* = 7.5 Hz, 2 H), 2.38 (s, 3 H), 2.10 (s, 3 H), 2.04 (s, 3 H), 1.89 (quin, *J* = 7.3 Hz, 2 H), 1.24 - 1.43 (m, 18 H), 0.90 (t, *J* = 7.2 Hz, 3 H).

¹³C NMR: (151 MHz, CDCl₃) δ 134.7, 133.6, 131.9, 131.6, 131.3, 128.4, 127.7, 127.3, 119.7 (q, *J* = 321.4 Hz), 47.6, 31.8, 29.5, 29.4, 29.3, 29.2, 28.8, 26.1, 22.6, 16.8, 14.0, 8.5, 8.4.

¹⁹F NMR: (565 MHz, CDCl₃) δ -79.0.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 49.12%, H: 6.18%, N: 6.61%, S: 10.09%.

Found: C: 49.35%, H: 5.97%, N: 6.33%, S: 10.08%.

**3-Butyl-1-(2-methoxyphenyl)-4,5-dimethyl-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (58)**



Following the general procedure, 15 mmol of bromide salt **31** were used for the anion exchange. The product was obtained as a brown oil. (7.5 g, 14 mmol, 93%).

¹H NMR: (300MHz, CDCl₃) δ 8.42 (s, 1 H), 7.50 - 7.59 (m, 1 H), 7.30 - 7.35 (m, 1 H), 7.04 - 7.14 (m, 2 H), 4.09 - 4.20 (m, 2 H), 3.81 (s, 3 H), 2.32 (s, 3 H), 2.03 (s, 3 H), 1.76 - 1.91 (m, 2 H), 1.40 (m, 2 H), 0.92 - 1.03 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 153.8, 134.2, 132.7, 129.0, 128.0, 126.5, 121.9, 121.2, 119.7 (q, *J* = 321.4 Hz), 112.3, 55.9, 47.3, 31.4, 19.4, 13.3, 8.5, 8.4.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.0.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 40.07%, H: 4.30%, N: 7.79%, S: 11.88%.

Found: C: 39.81%, H: 4.58%, N: 7.95%, S: 11.95%.

**1-(2-Methoxyphenyl)-4,5-dimethyl-3-octyl-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (59)**



Following the general procedure, 15 mmol of bromide salt **32** were used for the anion exchange. The product was obtained as a brown oil. (6.4 g, 11 mmol, 72%).

¹H NMR: (300MHz, CDCl₃) δ 8.43 (s, 1 H), 7.49 - 7.58 (m, 1 H), 7.30 - 7.36 (m, 1 H), 7.06 - 7.14 (m, 2 H), 4.09 - 4.19 (m, 2 H), 3.82 (s, 3 H), 2.32 (s, 3 H), 2.03 (s, 3 H), 1.85 (quin, *J* = 7.4 Hz, 2 H), 1.21 - 1.41 (m, 10 H), 0.81 - 0.90 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 153.8, 134.3, 132.7, 129.0, 128.0, 126.4, 121.3, 121.3, 119.7 (q, *J* = 321.4 Hz), 112.3, 55.9, 47.5, 31.6, 29.5, 28.9, 28.8, 26.1, 22.5, 13.9, 8.5, 8.4.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.0.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 44.36%, H: 5.25%, N: 7.06%, S: 10.77%.

Found: C: 44.68%, H: 5.23%, N: 6.71%, S: 10.84%.

**3-Dodecyl-1-(2-methoxyphenyl)-4,5-dimethyl-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (60)**



Following the general procedure, 12 mmol of bromide salt **33** were used for the anion exchange. The product was obtained as a brown oil. (6.1 g, 9 mmol, 77%).

¹H NMR: (300MHz, CDCl₃) δ 8.42 (s, 1 H), 7.50 - 7.57 (m, 1 H), 7.30 - 7.36 (m, 1 H), 7.05 - 7.13 (m, 2 H), 4.09 - 4.18 (m, 2 H), 3.82 (s, 3 H), 2.32 (s, 3 H), 2.03 (s, 3 H), 1.78 - 1.91 (m, 2 H), 1.14 - 1.43 (m, 18 H), 0.81 - 0.91 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 153.8, 134.2, 132.7, 129.0, 128.0, 126.4, 121.3, 121.3, 119.7 (q, *J* = 321.4 Hz), 112.3, 55.9, 47.5, 31.8, 29.5, 29.4, 29.3, 29.2, 28.9, 26.1, 22.6, 14.0, 8.5, 8.4.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.0.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 47.92%, H: 6.03%, N: 6.45%, S: 9.84%.

Found: C: 47.71%, H: 6.02%, N: 6.10%, S: 9.92%.

**3-Butyl-1-(2,4-difluorophenyl)-4,5-dimethyl-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (61)**



Following the general procedure, 18 mmol of bromide salt **34** were used for the anion exchange. The product was obtained as a brown oil. (7.8 g, 14 mmol, 79%).

¹H NMR: (300MHz, CDCl₃) δ 8.65 (s, 1 H), 7.57 - 7.72 (m, 1 H), 7.03 - 7.19 (m, 2 H), 4.10 - 4.24 (m, 2 H), 2.35 (s, 3 H), 2.11 (s, 3 H), 1.86 (quin, *J* = 7.6 Hz, 2 H), 1.32 - 1.52 (m, 2 H), 0.92 - 1.06 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 164.2 (dd, *J* = 256.3, 10.7 Hz), 156.9 (dd, 256.3, 12.5 Hz), 134.8, 130.5, 130.4, 128.9, 127.4, 119.9 (q, *J* = 321.3 Hz), 113.1 (dd, *J* = 22.7, 3.6 Hz), 105.6 (dd, *J* = 26.8, 4.2 Hz), 47.7, 31.3, 19.5, 13.3, 8.6, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.0, -102.4, -117.0.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 37.43%, H: 3.51%, N: 7.70%, S: 11.76%.

Found: C: 37.80%, H: 3.65%, N: 7.98%, S: 11.45%.

**1-(2,4-Difluorophenyl)-4,5-dimethyl-3-octyl-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (62)**



Following the general procedure, 15 mmol of bromide salt **35** were used for the anion exchange. The product was obtained as a brown oil. (8.7 g, 14 mmol, 96%).

¹H NMR: (300MHz, CDCl₃) δ 8.64 (s, 1 H), 7.59 - 7.72 (m, 1 H), 7.03 - 7.19 (m, 2 H), 4.16 (t, *J* = 7.6 Hz, 2 H), 2.35 (s, 3 H), 2.11 (s, 3 H), 1.82 - 1.94 (m, 2 H), 1.25 - 1.38 (m, 10 H), 0.80 - 0.92 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 164.2 (dd, *J* = 256.3, 10.7 Hz), 156.9 (dd, 256.3, 12.5 Hz), 134.8, 130.5, 130.4, 128.9, 127.4, 119.9 (q, *J* = 321.3 Hz), 113.1 (dd, *J* = 22.7, 3.6 Hz), 105.6 (dd, *J* = 26.8, 4.2 Hz), 48.0, 31.6, 29.4, 28.9, 28.8, 26.2, 22.5, 14.0, 8.6, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.0, -102.4, -117.0.


Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 41.93%, H: 4.52%, N: 6.99%, S: 10.66%.

Found: C: 41.69%, H: 4.60%, N: 6.60%, S: 10.52%.

**1-(2,4-Difluorophenyl)-3-dodecyl-4,5-dimethyl-1*H*-imidazol-3-ium
bis(trifluoromethylsulfonyl)amide (63)**



Following the general procedure, 13 mmol of bromide salt **36** were used for the anion exchange. The product was obtained as a brown oil. (7.1 g, 11 mmol, 83%).

¹H NMR: (300MHz, CDCl₃) δ 8.64 (s, 1 H), 7.60 - 7.73 (m, 1 H), 7.02 - 7.20 (m, 2 H), 4.16 (t, *J* = 7.6 Hz, 2 H), 2.35 (s, 3 H), 2.12 (s, 3 H), 1.81 - 1.95 (m, 2 H), 1.23 - 1.37 (m, 18 H), 0.83 - 0.93 (m, 3 H).

¹³C NMR: (75 MHz, CDCl₃) δ 164.2 (dd, *J* = 256.3, 10.7 Hz), 156.9 (dd, 256.3, 12.5 Hz), 134.8, 130.5, 130.4, 128.9, 127.4, 119.9 (q, *J* = 321.3 Hz), 113.1 (dd, *J* = 22.7, 3.6 Hz), 105.6 (dd, *J* = 26.8, 4.2 Hz), 48.0, 31.9, 29.6, 29.5, 29.5, 29.4, 29.3, 28.9, 26.3, 22.7, 14.1, 8.6, 8.5.

¹⁹F NMR: (282 MHz, CDCl₃) δ -79.0, -102.3, -117.1.

Melting point: liquid at room temperature.

Elemental analysis:

Calculated: C: 45.66%, H: 5.36%, N: 6.39%, S: 9.75%.

Found: C: 45.75%, H: 5.55%, N: 6.02%, S: 9.82%.

S4 Electrochemical measurements




Figure S1. LSV of compounds **37–39**.




Figure S2. LSV of compounds **40–42**.




Figure S3. LSV of compounds **43–45**.




Figure S4. LSV of compounds **49** and **50**.




Figure S5. LSV of compounds **52** and **53**.




Figure S6. LSV of compounds **55–57**.




Figure S7. LSV of compounds **58–60**.




Figure S8. LSV of compounds **61–63**.

S5 Viscosity measurements




Figure S9. Viscosity measurements of compounds **37–39**.




Figure S10. Viscosity measurements of compounds **40–42**.




Figure S11. Viscosity measurements of compounds **43–45**.




Figure S12. Viscosity measurements of compounds **46** and **47**.




Figure S13. Viscosity measurements of compounds **49** and **50**.




Figure S14. Viscosity measurements of compounds **52** and **53**.




Figure S15. Viscosity measurements of compounds **55–57**.




Figure S16. Viscosity measurements of compounds **58–60**.




Figure S17. Viscosity measurements of compounds **61–63**.

S6 Thermogravimetric analysis




Figure S18. Thermogravimetric analysis of compound **37**.




Figure S19. Thermogravimetric analysis of compound **38**.




Figure S20. Thermogravimetric analysis of compound **39**.




Figure S21. Thermogravimetric analysis of compound **40**.




Figure S22. Thermogravimetric analysis of compound **41**.




Figure S23. Thermogravimetric analysis of compound **42**.




Figure S24. Thermogravimetric analysis of compound **43**.




Figure S25. Thermogravimetric analysis of compound **44**.




Figure S26. Thermogravimetric analysis of compound **45**.




Figure S27. Thermogravimetric analysis of compound **46**.




Figure S28. Thermogravimetric analysis of compound **47**.




Figure S29. Thermogravimetric analysis of compound **48**.




Figure S30. Thermogravimetric analysis of compound **49**.




Figure S31. Thermogravimetric analysis of compound **50**.




Figure S32. Thermogravimetric analysis of compound **51**.




Figure S33. Thermogravimetric analysis of compound **52**.




Figure S34. Thermogravimetric analysis of compound **53**.




Figure S35. Thermogravimetric analysis of compound **54**.




Figure S36. Thermogravimetric analysis of compound **55**.




Figure S37. Thermogravimetric analysis of compound **56**.




Figure S38. Thermogravimetric analysis of compound **57**.




Figure S39. Thermogravimetric analysis of compound **58**.




Figure S40. Thermogravimetric analysis of compound **59**.




Figure S41. Thermogravimetric analysis of compound **60**.




Figure S42. Thermogravimetric analysis of compound **61**.




Figure S43. Thermogravimetric analysis of compound **62**.




Figure S44. Thermogravimetric analysis of compound **63**.

S7 NMR-Spectra




Figure S45. ¹H NMR of compound 4.




Figure S46. ¹³C NMR of compound 4.




Figure S47. ¹H NMR of compound **5**.




Figure S48. ¹³C NMR of compound **5**.




Figure S49. ¹⁹F NMR of compound **5**.




Figure S50. ¹H NMR of compound 6.




Figure S51. ¹³C NMR of compound 6.




Figure S52. ¹⁹F NMR of compound 6.




Figure S53. ^1H NMR of compound 9.




Figure S54. ^{13}C NMR of compound 9.




Figure S55. ^{19}F NMR of compound 9.




Figure S56. ^1H NMR of compound 10.




Figure S57. ^{13}C NMR of compound 10.




Figure S58. ^1H NMR of compound 11.




Figure S59. ^{13}C NMR of compound 11.




Figure S60. ^1H NMR of compound 12.




Figure S61. ^{13}C NMR of compound 12.




Figure S62. ¹H NMR of compound 13.




Figure S63. ¹³C NMR of compound 13.




Figure S64. ¹H NMR of compound 14.




Figure S65. ^{13}C NMR of compound 14.




Figure S66. ^1H NMR of compound 15.




Figure S67. ^{13}C NMR of compound 15.




Figure S68. ¹H NMR of compound 16.




Figure S69. ¹³C NMR of compound 16.




Figure S70. ¹H NMR of compound 17.




Figure S71. ^{13}C NMR of compound 17.




Figure S72. ^1H NMR of compound 18.




Figure S73. ^{13}C NMR of compound 18.




Figure S74. ¹H NMR of compound 19.




Figure S75. ¹³C NMR of compound 19.




Figure S76. ¹H NMR of compound 20.




Figure S77. ^{13}C NMR of compound 20.




Figure S78. ^1H NMR of compound 21.




Figure S79. ^{13}C NMR of compound 21.




Figure S80. ^1H NMR of compound 22.




Figure S81. ^{13}C NMR of compound 22.




Figure S82. ^{19}F NMR of compound 22.




Figure S83. ¹H NMR of compound 23.




Figure S84. ¹³C NMR of compound 23.




Figure S85. ¹⁹F NMR of compound 23.





Figure S86. ^1H NMR of compound 24.






Figure S89. ^1H NMR of compound 25.




Figure S90. ^{13}C NMR of compound 25.




Figure S91. ^{19}F NMR of compound 25.




Figure S92. ¹H NMR of compound 26.




Figure S93. ¹³C NMR of compound 26.




Figure S94. ¹⁹F NMR of compound 26.




Figure S95. ¹H NMR of compound 27.




Figure S96. ¹³C NMR of compound 27.




Figure S97. ¹⁹F NMR of compound 27.




Figure S98. ^1H NMR of compound 28.




Figure S99. ^{13}C NMR of compound 28.




Figure S100. ^1H NMR of compound 29.




Figure S101. ¹³C NMR of compound 29.




Figure S102. ¹H NMR of compound 30.




Figure S103. ¹³C NMR of compound 30.




Figure S104. ^1H NMR of compound 31.




Figure S105. ^{13}C NMR of compound 31.




Figure S106. ^1H NMR of compound 32.




Figure S107. ¹³C NMR of compound 32.




Figure S108. ¹H NMR of compound 33.




Figure S109. ¹³C NMR of compound 33.




Figure S110. ¹H NMR of compound 34.




Figure S111. ¹³C NMR of compound 34.




Figure S112. ¹⁹F NMR of compound 34.




Figure S113. ¹H NMR of compound 35.




Figure S114. ¹³C NMR of compound 35.




Figure S115. ¹⁹F NMR of compound 35.




Figure S116. ¹H NMR of compound 36.




Figure S117. ¹³C NMR of compound 36.




Figure S118. ¹⁹F NMR of compound 36.




Figure S119. ¹H NMR of compound 37.




Figure S120. ¹³C NMR of compound 37.




Figure S121. ¹H NMR of compound 38.




Figure S122. ¹³C NMR of compound **38**.




Figure S121. ¹H NMR of compound **39**.




Figure S122. ¹³C NMR of compound **39**.




Figure S123. ^1H NMR of compound 40.




Figure S124. ^{13}C NMR of compound 40.




Figure S125. ^1H NMR of compound 41.




Figure S126. ¹³C NMR of compound 41.




Figure S127. ¹H NMR of compound 42.




Figure S128. ¹³C NMR of compound 42.




Figure S129. ¹H NMR of compound 43.




Figure S130. ¹³C NMR of compound 43.




Figure S131. ¹H NMR of compound 44.




Figure S132. ¹³C NMR of compound 44.




Figure S133. ¹H NMR of compound 45.




Figure S134. ¹³C NMR of compound 45.




Figure S135. ^1H NMR of compound 46.




Figure S136. ^{13}C NMR of compound 46.




Figure S137. ^1H NMR of compound 47.




Figure S138. ¹³C NMR of compound 47.




Figure S139. ¹H NMR of compound 48.




Figure S140. ¹³C NMR of compound 48.




Figure S141. ¹H NMR of compound **49**.




Figure S142. ¹³C NMR of compound **49**.







Figure S143. ¹⁹F NMR of compound **49**.






Figure S147. ^1H NMR of compound 51.




Figure S148. ^{13}C NMR of compound 51.




Figure S149. ^{19}F NMR of compound 51.




Figure S150. ¹H NMR of compound 52.




Figure S151. ¹³C NMR of compound 52.




Figure S152. ¹⁹F NMR of compound 52.




Figure S153. ¹H NMR of compound **53**.




Figure S154. ¹³C NMR of compound **53**.




Figure S155. ¹⁹F NMR of compound **53**.




Figure S156. ¹H NMR of compound **54**.




Figure S157. ¹³C NMR of compound **54**.







Figure S158. ¹⁹F NMR of compound **54**.






Figure S162. ¹³C NMR of compound 56.




Figure S163. ¹H NMR of compound 57.




Figure S164. ¹³C NMR of compound 57.




Figure S165. ¹H NMR of compound 58.




Figure S166. ¹³C NMR of compound 58.




Figure S167. ¹H NMR of compound 59.




Figure S168. ^{13}C NMR of compound 59.




Figure S169. ^1H NMR of compound 60.




Figure S170. ^{13}C NMR of compound 60.







Figure S175. ^{13}C NMR of compound 62.




Figure S176. ^{19}F NMR of compound 62.




Figure S177. ^1H NMR of compound 63.




Figure S178. ^{13}C NMR of compound 63.




Figure S179. ^{19}F NMR of compound 63.

S8 Cartesian coordinates of optimized structures

Cation [PhImC₄H₉]⁺

C	-4.83860800	-0.92889800	0.01867700
C	-3.78475000	-1.80958300	-0.21698200
C	-2.47526400	-1.33864800	-0.25606300
C	-2.24486400	0.01688000	-0.04160900
C	-3.28412500	0.91058400	0.19838300
C	-4.58907000	0.42738500	0.22201900
H	-5.85583700	-1.29926200	0.04162700
H	-3.98008800	-2.86109700	-0.38521800
H	-1.65255100	-2.00881300	-0.47466400
H	-3.07734700	1.95786700	0.38199500
H	-5.40814500	1.10990700	0.41019300
N	-0.89170300	0.51231700	-0.07150800
C	-0.43145300	1.58130200	-0.82332900
C	0.13496600	0.01337700	0.63291100
C	0.89694300	1.71130300	-0.55685300
H	-1.08180300	2.13059100	-1.48100800
H	0.07292300	-0.80790800	1.32599900
H	1.62517900	2.40736900	-0.93538500
C	2.58674000	0.46404600	0.88079000
C	3.48044800	-0.22374300	-0.14925900
H	2.46726500	-0.14930100	1.77496300
H	2.99974600	1.42500100	1.19183700
C	4.88174100	-0.49117100	0.40989800
H	3.01423900	-1.16578800	-0.45766600
H	3.55341200	0.40183700	-1.04524700
C	5.79092200	-1.17927300	-0.60951900
H	5.33257500	0.45602900	0.72617200
H	4.80094500	-1.11131000	1.30967200
H	6.78146400	-1.35937300	-0.18814700
H	5.37998300	-2.14429500	-0.91858500

H	5.91685300	-0.56519600	-1.50542800
N	1.23019200	0.72516500	0.35357800

Cation 37

C	-4.31091300	-0.97087600	-1.06662800
C	-3.00641700	-0.49835000	-1.19000800
C	-2.24742800	-0.31590000	-0.03851700
C	-2.75825300	-0.58523000	1.22726900
C	-4.06527000	-1.05091800	1.33787800
C	-4.83866400	-1.24350000	0.19378300
H	-4.91341400	-1.11946100	-1.95389000
H	-2.58713400	-0.26593000	-2.16153100
H	-2.14155500	-0.44241600	2.10616000
H	-4.47590300	-1.26864900	2.31579500
H	-5.85445700	-1.60754400	0.28537400
N	-0.89644700	0.17670000	-0.16033700
C	0.13477700	-0.53305100	-0.63287200
C	-0.45975800	1.46506900	0.15645100
H	0.08925900	-1.56157500	-0.94760400
C	0.87865200	1.50443200	-0.13950600
C	-1.38344700	2.50797800	0.67793700
H	-2.27465400	2.58736400	0.05144900
H	-1.71196700	2.28208000	1.69514000
H	-0.88694600	3.47710500	0.69007300
C	1.86266900	2.61594900	-0.03122100
H	2.27804900	2.87931800	-1.00769000
H	1.37779600	3.50307500	0.37309800
H	2.69202400	2.35879300	0.63180300
C	2.57244300	-0.20554100	-1.00784600
C	3.37633700	-0.69021600	0.19800200
H	3.06630500	0.62985700	-1.50490900
H	2.45459000	-1.00004400	-1.74634200
C	4.78892800	-1.12699300	-0.20162800

H	3.43311100	0.10695800	0.94613400
H	2.84570900	-1.52504000	0.66885800
C	5.60343700	-1.62554900	0.99300500
H	4.72398600	-1.91651400	-0.95876000
H	5.30704700	-0.28609200	-0.67621500
H	6.60464900	-1.93003700	0.68285700
H	5.71276400	-0.84479300	1.75087300
H	5.12487200	-2.48751900	1.46598800
N	1.21834800	0.24433700	-0.63441300

Cation 40

C	4.54467400	-0.83461400	0.10087000
C	3.74374700	-0.74494200	1.24669800
C	2.40743000	-0.37228400	1.16421500
C	1.86481300	-0.08081000	-0.08303900
C	2.63414400	-0.15276600	-1.23872400
C	3.96886600	-0.53305100	-1.13804500
H	4.17091800	-0.97373200	2.21612400
H	1.79272500	-0.31409900	2.05439200
H	2.19985100	0.09599500	-2.19976300
H	4.57261100	-0.58871600	-2.03619100
N	0.48286400	0.32270600	-0.17734600
C	-0.03488200	1.56943800	0.18050500
C	-0.50425400	-0.44000900	-0.66036200
C	-1.37617800	1.52863000	-0.10161200
H	-0.39388400	-1.45361900	-1.00577400
C	-2.96233700	-0.26453600	-1.00389400
C	-3.71996300	-0.83423000	0.19475800
H	-2.80044600	-1.02916500	-1.76525500
H	-3.51564800	0.54946300	-1.47312200
C	-5.10495700	-1.35224600	-0.20426400
H	-3.13047300	-1.64473400	0.63722900
H	-3.82097200	-0.06344300	0.96555300

C	-5.87176400	-1.93668900	0.98299900
H	-5.68258100	-0.53461000	-0.64994500
H	-4.99648000	-2.11433200	-0.98420000
H	-6.85423900	-2.29779600	0.67362100
H	-5.33232100	-2.77802900	1.42672600
H	-6.02360800	-1.18628900	1.76386600
N	-1.63727700	0.26329400	-0.62987900
C	0.82445400	2.65472600	0.72465200
H	1.18818300	2.41452700	1.72647900
H	1.69569700	2.81787800	0.08636900
H	0.26285700	3.58596300	0.78208100
C	-2.43048300	2.56866200	0.04800400
H	-2.87224900	2.83261600	-0.91669300
H	-3.23441800	2.23788200	0.70971700
H	-2.00110800	3.47374600	0.47468700
C	5.98226500	-1.26844300	0.20077500
H	6.44357100	-0.90596900	1.12108200
H	6.05137800	-2.36093300	0.20718700
H	6.56808000	-0.90561600	-0.64481100

Cation 49

C	-3.57189400	-0.29728000	-0.01566800
C	-2.81462300	-0.25705700	-1.18588800
C	-1.45156200	0.00638800	-1.11758000
C	-0.86931000	0.22715300	0.12633900
C	-1.61522900	0.19368700	1.29955600
C	-2.97785700	-0.07712800	1.22512600
H	-3.28664600	-0.42979200	-2.14405500
H	-0.84851700	0.03137800	-2.01644500
H	-1.14202900	0.38752200	2.25419100
H	-3.57608800	-0.10312600	2.12623200
N	0.54192900	0.51052800	0.20061600
C	1.16285300	1.70270400	-0.18206700

C	1.46455200	-0.33116300	0.68439200
C	2.49843600	1.54552200	0.08590300
H	1.27071200	-1.32704400	1.04480500
C	3.93250800	-0.36989300	0.99423300
C	4.61815000	-1.02184900	-0.20579300
H	3.71375900	-1.10552500	1.76972100
H	4.56174400	0.39910900	1.44299900
C	5.95717800	-1.65569200	0.18354100
H	3.95259800	-1.78302300	-0.62758400
H	4.77656800	-0.27436600	-0.98976900
C	6.65143600	-2.32309400	-1.00463100
H	6.61152900	-0.88652200	0.60890000
H	5.79222200	-2.39385700	0.97640700
H	7.60192400	-2.76614600	-0.70215000
H	6.03292600	-3.11917000	-1.42816700
H	6.85880500	-1.60050500	-1.79880100
N	2.65313300	0.26896600	0.62898800
C	0.39796200	2.85516700	-0.72976000
H	0.01194200	2.64453600	-1.72995400
H	-0.45234700	3.09986500	-0.08920500
H	1.03872600	3.73323300	-0.79399500
C	3.63861800	2.48585100	-0.09009600
H	4.11152900	2.72400500	0.86643000
H	4.40285600	2.07413500	-0.75327100
H	3.28712800	3.41872600	-0.52792200
C	-5.04254100	-0.63788000	-0.09185900
F	-5.73208100	-0.09309800	0.92717300
F	-5.22663300	-1.97497900	-0.03553500
F	-5.59204500	-0.20442500	-1.24164800

S9 References

1. Kuriyama, M.; Matsuo, S.; Shinozawa, M.; Onomura, O. *Org. Lett.* **2013**, *15*, 2716–2719. doi:10.1021/ol4010189
2. Szpunar, M.; Loska, R. *Eur. J. Org. Chem.* **2015**, *10*, 2133–2137. doi:10.1002/ejoc.201500072
3. Mityanov, V. S.; Perevalov, V. P.; Tkach, I. I. *Chem. Heterocycl. Comp.* **2013**, *48*, 1793–1800. doi:10.1007/s10593-013-1210-8
4. Kuriyama, M.; Kujirada, S.; Tsukuda, K.; Onomura, O. *Adv. Synth. Catal.* **2017**, *359*, 1043–1048. doi:10.1002/adsc.201601105